PWM
QNCX icon

Prentice Wealth Management’s Quince Therapeutics QNCX Stock Holding History

Prentice Wealth Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$1K – 155
2022
Q2 		$1K Buy
+2
New +$1.41K ﹤0.01% 133
2021
Q4 		– Hold
0
– -$6K – 254
2021
Q3 		– Hold
0
– – – 271
2021
Q2 		– Hold
0
– – – 286
2021
Q1 		– Hold
0
– – – 289

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Prentice Wealth Management's QNCX Position: Q3 2022 in Review

Prentice Wealth Management sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 2 shares — an estimated $1K sold.

Prentice Wealth Management first reported a position in QNCX in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • Prentice Wealth Management reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prentice Wealth Management sold 2 Quince Therapeutics shares in Q3 2022, an estimated $1K.
  • Prentice Wealth Management first reported a position in Quince Therapeutics in Q2 2022 and held it in 1 quarter.
  • Prentice Wealth Management's Quince Therapeutics position peaked at $1K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Prentice Wealth Management's 13F filing for Q3 2022, filed 19 Oct 2022.